Assistant Professor of Oncology and Medicine
Director, Myeloma Program
Contact Information:
To Make and Appointment:
New Patients: 410-955-8964
Return Patients: 410-955-8893
Administrative Office: 443-287-7104
fax: 410-502-7213
Clinical/Academic Interests:
Multiple myeloma, MGUS, AL amyloidosis, other plasma cell dyscrasias
Research Interests:
Dr. Huff’s major research interests focus on the development of novel therapeutic approaches for the treatment of multiple myeloma and other plasma cell dyscrasias. Her current efforts are focused on the clinical translation of novel approaches targeting myeloma stem cells both biologically and immunologically and on efforts to improve the efficacy and reduce the toxicity of allogeneic bone marrow transplantation for multiple myeloma and related disorders.
Education:
1986 B.S., Zoology, Duke University, Durham, North Carolina.
1992 M.D., Baylor College of Medicine, Houston, Texas.
Academic Positions:
1996-1997 Assistant Chief of Service, Osler Medical Service, Johns Hopkins University
1997-1999 Assistant Professor of Medicine, Johns Hopkins University
2001-present Assistant Professor of Oncology, Johns Hopkins University
2004-present Director, Myeloma Program, Johns Hopkins University
2005-present Assistant Professor of Medicine, Johns Hopkins University
Selected Publications:
- Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood 2005: Sept 8, [Epub ahead of print].
- Huff CA, Matsui W, Smith BD, Jones RJ. Strategies to eliminate cancer stem cells: Clinical implications. Eur J Cancer, in press.
- Angstreich GR, Matsui W, Huff CA, Vala MS, Barber J, Hawkins AL, Griffin CA, Smith BD, Jones RJ Effects of Imatinib and Interferon on Primitive Chronic Myeloid Leukaemia Progenitors, Br J Haemotol. 130(3): 373-81, 2005.
- Matsui W, Douglas Smith B, Vala M, Beal N, Huff CA, Diehl LF, Jones RJ. Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia. Br J Haematol. 2005 Mar; 128(6):853-62.
- Vogelsang G, Huff CA, Higman M. Stem cell transplantation. In: George JN, Williams ME, eds. American Society of Hematology Self-Assessment Program. Malden, MA: Blackwell Publishing; 2005: 273-296.
- Matsui WH, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ. Characterization of clonogenic multiple myeloma cells. Blood, 103(6): 2332-6, 2004. Epub 2003 Nov 20.
- Huff CA, Fuchs EJ, Noga SJ, O’Donnell PV, Ambinder RF, Diehl L, Borrello I, Vogelsang GB, Miller CB, Flinn IA, Brodsky RA, Marcellus D, Jones RJ. Long-term follow-up of T cell–depleted allogeneic bone marrow transplantation in refractory multiple myeloma: Importance of allogeneic T cells. Biol Blood and Marrow Transplantation, 9:312-319, 2003.
- Matsui W, Huff CA, Vala M, Barber J, Smith BD, Jones RJ. Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation, Br J Haematol, 121:251-8, 2003.
- Huff CA. Plasma Cell Dyscrasias. In: Miller R, Sisson S, Ashar S, eds. The Johns Hopkins Internal Medicine Board Review. Philadelphia, PA: Mosby Publishing; 2003: 437-441.
- Vogelsang G, Huff CA. Stem cell transplantation. In: George JN, Williams ME, eds. American Society of Hematology Self-Assessment Program. Malden, MA: Blackwell Publishing; 2003: 230-248.
- Huff CA and Jones RJ. Bone marrow transplantation for multiple myeloma: where we are today. Curr Opin Oncology, 14: 147-51, 2002.
- Huff CA. Multiple myeloma: An update on treatment options. Fellow Reporter, 6(3): 14-16, 2001.
